Literature DB >> 15383408

Myopericarditis following smallpox vaccination.

Mark K Arness1, Robert E Eckart, Suzanne S Love, J Edwin Atwood, Timothy S Wells, Renata J M Engler, Limone C Collins, Sharon L Ludwig, James R Riddle, John D Grabenstein, David N Tornberg.   

Abstract

Myopericarditis has been a rare or unrecognized event after smallpox vaccinations with the New York City Board of Health strain of vaccinia virus (Dryvax; Wyeth Laboratories, Marietta, Pennsylvania). In this article, the authors report an attributable incidence of at least 140 clinical cases of myopericarditis per million primary smallpox vaccinations with this strain of vaccinia virus. Fifty-eight males and one female aged 21-43 years with confirmed or probable acute myopericarditis were detected following vaccination of 492,730 US Armed Forces personnel from December 15, 2002, through September 30, 2003. The cases were identified through sentinel reporting to military headquarters, active surveillance using the Defense Medical Surveillance System, or reports to the Vaccine Adverse Event Reporting System. The observed incidence (16.11/100,000) of myopericarditis over a 30-day observation window among 347,516 primary vaccinees was nearly 7.5-fold higher than the expected rate of 2.16/100,000 (95% confidence interval: 1.90, 2.34) among nonvaccinated, active-duty military personnel, while the incidence of 2.07/100,000 among 145,155 revaccinees was not statistically different from the expected background rate. The cases were predominantly male (58/59; 98.3%) and White (51/59; 86.4%), both statistically significant associations (p = 0.0147 and p = 0.05, respectively).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15383408     DOI: 10.1093/aje/kwh269

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  38 in total

1.  Non-specific "non-effects" of vaccination.

Authors:  Paul E M Fine
Journal:  BMJ       Date:  2004-12-04

2.  Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

Authors:  Janie Parrino; Lewis H McCurdy; Brenda D Larkin; Ingelise J Gordon; Steven E Rucker; Mary E Enama; Richard A Koup; Mario Roederer; Robert T Bailer; Zoe Moodie; Lin Gu; Lihan Yan; Barney S Graham
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

3.  Ischemic cardiac events and other adverse events following ACAM2000(®) smallpox vaccine in the Vaccine Adverse Event Reporting System.

Authors:  Michael M McNeil; Maria Cano; Elaine R Miller; Brett W Petersen; Renata J M Engler; Marthe G Bryant-Genevier
Journal:  Vaccine       Date:  2014-06-18       Impact factor: 3.641

4.  Vaccination and risk of lone atrial fibrillation in the active component United States military.

Authors:  Michael M McNeil; Susan K Duderstadt; Jennifer F Sabatier; Gina G Ma; Jonathan Duffy
Journal:  Hum Vaccin Immunother       Date:  2019-01-08       Impact factor: 3.452

5.  UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV.

Authors:  Bart G Jones; Robert E Sealy; Xiaoyan Zhan; Pamela J Freiden; Sherri L Surman; James L Blanchard; Julia L Hurwitz
Journal:  Vaccine       Date:  2012-03-14       Impact factor: 3.641

6.  Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.

Authors:  Richard N Greenberg; Edgar Turner Overton; David W Haas; Ian Frank; Mitchell Goldman; Alfred von Krempelhuber; Garth Virgin; Nicole Bädeker; Jens Vollmar; Paul Chaplin
Journal:  J Infect Dis       Date:  2012-12-07       Impact factor: 5.226

7.  Vaccinia virus A35R inhibits MHC class II antigen presentation.

Authors:  Kristina E Rehm; Ramsey F Connor; Gwendolyn J B Jones; Kenneth Yimbu; Rachel L Roper
Journal:  Virology       Date:  2009-12-02       Impact factor: 3.616

8.  Immune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected mice.

Authors:  Henning Lauterbach; Ronny Kassub; Juliane Pätzold; Jana Körner; Michael Brückel; Admar Verschoor; Paul Chaplin; Mark Suter; Hubertus Hochrein
Journal:  PLoS One       Date:  2010-03-11       Impact factor: 3.240

Review 9.  ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.

Authors:  Aysegul Nalca; Elizabeth E Zumbrun
Journal:  Drug Des Devel Ther       Date:  2010-05-25       Impact factor: 4.162

10.  Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.

Authors:  Stephen R Walsh; Marissa B Wilck; David J Dominguez; Elise Zablowsky; Shringkhala Bajimaya; Lisa S Gagne; Kelly A Verrill; Jane A Kleinjan; Alka Patel; Ying Zhang; Heather Hill; Aruna Acharyya; David C Fisher; Joseph H Antin; Michael S Seaman; Raphael Dolin; Lindsey R Baden
Journal:  J Infect Dis       Date:  2013-03-12       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.